日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy

SMARCA4基因突变导致癌细胞增强子图谱发生内在缺陷,并产生免疫治疗耐药性。

Yawen Wang ,Ismail M Meraz ,Md Qudratullah ,Sasikumar Kotagiri ,Yanyan Han ,Yuanxin Xi ,Jing Wang ,Kadir C Akdemir ,Jack A Roth ,Yonathan Lissanu

Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer

增强子重编程是SMARCA2降解剂在SMARCA4突变癌症中发挥治疗作用的基础。

Sasikumar Kotagiri ,Nicholas Blazanin ,Yuanxin Xi ,Yanyan Han ,Md Qudratullah ,Xiaobing Liang ,Yawen Wang ,Poonam Pandey ,Hira Mazhar ,Truong Nguyen Lam ,Anand Kamal Singh ,Jing Wang ,Yonathan Lissanu

Therapeutic modulation of ROCK overcomes metabolic adaptation of cancer cells to OXPHOS inhibition and drives synergistic anti-tumor activity

ROCK 的治疗调节可克服癌细胞对 OXPHOS 抑制的代谢适应并促进协同抗肿瘤活性

Nicholas Blazanin, Xiaobing Liang, Iqbal Mahmud, Eiru Kim, Sara Martinez, Lin Tan, Waikin Chan, Nazanin Esmaeili Anvar, Min Jin Ha, Md Qudratullah, Rosalba Minelli, Michael Peoples, Philip Lorenzi, Traver Hart, Yonathan Lissanu

MN1 overexpression with varying tumor grade is a promising predictor of survival of glioma patients

不同肿瘤等级的 MN1 过度表达是预测胶质瘤患者生存的有力指标

Masum Saini, Ajaya Nand Jha, Rajiv Tangri, Md Qudratullah, Sher Ali